Nilo Therapeutics Launches With US$101 Mln Series A Financing 

KUALA LUMPUR, Oct 9 (Bernama) -- Nilo Therapeutics, a biotechnology company, emerged from stealth today with a US$101 million Series A financing, aiming to revolutionise immunomodulation by targeting neural circuits that regulate the immune system. (US$1=RM4.21)

The financing was led by The Column Group (TCG), DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments.

Coinciding with the launch, Dr Kim Seth was appointed Chief Executive Officer and Board Director, according to Nilo in a statement.

Dr Seth said he was honoured to lead Nilo in building a new generation of therapies that harness the brain-immune axis to transform the treatment of autoimmune and inflammatory conditions.

Meanwhile, Nilo Chief Scientific Officer, Dr Laurens Kruidenier said Dr Seth’s leadership would accelerate Nilo’s efforts to translate breakthrough neuro-immunology into medicines.

A biotech veteran, Dr Seth previously helped scale Repare Therapeutics from early-stage to initial public offering (IPO) and has held leadership roles at Pfizer and Goldman Sachs.

The Series A funding will support the setup of Nilo’s laboratories in New York City, expansion of its research and development team, and advancement of preclinical programmes.

Founded by leading scientists Dr Charles Zuker of Columbia University, Dr Ruslan Medzhitov of Yale University and Dr Steve Liberles of Harvard University, Nilo was established in collaboration with TCG to translate breakthroughs in neuro-immunology into new therapeutic strategies.

Nilo aims to restore immune homeostasis via central “master regulator” brain circuits identified in Dr Zuker’s laboratory. This neuro-immunology approach offers a new path beyond traditional immunosuppression, with the potential to impact a wide range of autoimmune and inflammatory diseases.

-- BERNAMA